Therefore, we selected the SPHK1 kinase inhibitor PF-543 and the S1P receptor inhibitor FTY720 for in vivo treatment of CML mice [43]. Here, SPHK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.